JP2019516352A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019516352A5 JP2019516352A5 JP2018551409A JP2018551409A JP2019516352A5 JP 2019516352 A5 JP2019516352 A5 JP 2019516352A5 JP 2018551409 A JP2018551409 A JP 2018551409A JP 2018551409 A JP2018551409 A JP 2018551409A JP 2019516352 A5 JP2019516352 A5 JP 2019516352A5
- Authority
- JP
- Japan
- Prior art keywords
- clone
- seq
- amino acid
- receptor
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 25
- 125000003275 alpha amino acid group Chemical group 0.000 claims 20
- 230000000139 costimulatory effect Effects 0.000 claims 16
- -1 OX-40 Proteins 0.000 claims 14
- 108091008874 T cell receptors Proteins 0.000 claims 13
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 13
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 12
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 12
- 239000002157 polynucleotide Substances 0.000 claims 12
- 102000040430 polynucleotide Human genes 0.000 claims 12
- 108091033319 polynucleotide Proteins 0.000 claims 12
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims 11
- 125000000539 amino acid group Chemical group 0.000 claims 11
- 239000000427 antigen Substances 0.000 claims 11
- 102000036639 antigens Human genes 0.000 claims 11
- 108091007433 antigens Proteins 0.000 claims 11
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 10
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 claims 10
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 claims 10
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 claims 10
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 claims 10
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims 10
- 102100029215 Signaling lymphocytic activation molecule Human genes 0.000 claims 8
- 230000004913 activation Effects 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 210000002865 immune cell Anatomy 0.000 claims 7
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 claims 6
- 102100032816 Integrin alpha-6 Human genes 0.000 claims 6
- 102100025390 Integrin beta-2 Human genes 0.000 claims 6
- 108010074687 Signaling Lymphocytic Activation Molecule Family Member 1 Proteins 0.000 claims 6
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 claims 5
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 claims 5
- 210000001744 T-lymphocyte Anatomy 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 102100024263 CD160 antigen Human genes 0.000 claims 4
- 102100038077 CD226 antigen Human genes 0.000 claims 4
- 102100038078 CD276 antigen Human genes 0.000 claims 4
- 101000761938 Homo sapiens CD160 antigen Proteins 0.000 claims 4
- 101000884298 Homo sapiens CD226 antigen Proteins 0.000 claims 4
- 101001078158 Homo sapiens Integrin alpha-1 Proteins 0.000 claims 4
- 101000994375 Homo sapiens Integrin alpha-4 Proteins 0.000 claims 4
- 101000994365 Homo sapiens Integrin alpha-6 Proteins 0.000 claims 4
- 101001046687 Homo sapiens Integrin alpha-E Proteins 0.000 claims 4
- 101000971538 Homo sapiens Killer cell lectin-like receptor subfamily F member 1 Proteins 0.000 claims 4
- 101000873418 Homo sapiens P-selectin glycoprotein ligand 1 Proteins 0.000 claims 4
- 101000633786 Homo sapiens SLAM family member 6 Proteins 0.000 claims 4
- 101000633782 Homo sapiens SLAM family member 8 Proteins 0.000 claims 4
- 101000633780 Homo sapiens Signaling lymphocytic activation molecule Proteins 0.000 claims 4
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims 4
- 102100025323 Integrin alpha-1 Human genes 0.000 claims 4
- 102100032818 Integrin alpha-4 Human genes 0.000 claims 4
- 102100022341 Integrin alpha-E Human genes 0.000 claims 4
- 102100022339 Integrin alpha-L Human genes 0.000 claims 4
- 102100021458 Killer cell lectin-like receptor subfamily F member 1 Human genes 0.000 claims 4
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 claims 4
- 102100034925 P-selectin glycoprotein ligand 1 Human genes 0.000 claims 4
- 102000014128 RANK Ligand Human genes 0.000 claims 4
- 108010025832 RANK Ligand Proteins 0.000 claims 4
- 102100029197 SLAM family member 6 Human genes 0.000 claims 4
- 102100029214 SLAM family member 8 Human genes 0.000 claims 4
- 102100027744 Semaphorin-4D Human genes 0.000 claims 4
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 claims 4
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 108040006849 interleukin-2 receptor activity proteins Proteins 0.000 claims 4
- 239000003446 ligand Substances 0.000 claims 4
- 230000019491 signal transduction Effects 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 2
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 claims 2
- 101710145634 Antigen 1 Proteins 0.000 claims 2
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims 2
- 102100027205 B-cell antigen receptor complex-associated protein alpha chain Human genes 0.000 claims 2
- 101710095183 B-cell antigen receptor complex-associated protein alpha chain Proteins 0.000 claims 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 2
- 108010056102 CD100 antigen Proteins 0.000 claims 2
- 108010017009 CD11b Antigen Proteins 0.000 claims 2
- 102100027207 CD27 antigen Human genes 0.000 claims 2
- 101150013553 CD40 gene Proteins 0.000 claims 2
- 108010062802 CD66 antigens Proteins 0.000 claims 2
- 102100027217 CD82 antigen Human genes 0.000 claims 2
- 101710139831 CD82 antigen Proteins 0.000 claims 2
- 102100035793 CD83 antigen Human genes 0.000 claims 2
- 102100024533 Carcinoembryonic antigen-related cell adhesion molecule 1 Human genes 0.000 claims 2
- 102100025137 Early activation antigen CD69 Human genes 0.000 claims 2
- 101000585551 Equus caballus Pregnancy-associated glycoprotein Proteins 0.000 claims 2
- 102100022086 GRB2-related adapter protein 2 Human genes 0.000 claims 2
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 claims 2
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 claims 2
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 2
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims 2
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 claims 2
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 claims 2
- 101000900690 Homo sapiens GRB2-related adapter protein 2 Proteins 0.000 claims 2
- 101001035237 Homo sapiens Integrin alpha-D Proteins 0.000 claims 2
- 101001046683 Homo sapiens Integrin alpha-L Proteins 0.000 claims 2
- 101001046668 Homo sapiens Integrin alpha-X Proteins 0.000 claims 2
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 claims 2
- 101001047640 Homo sapiens Linker for activation of T-cells family member 1 Proteins 0.000 claims 2
- 101001090688 Homo sapiens Lymphocyte cytosolic protein 2 Proteins 0.000 claims 2
- 101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 claims 2
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims 2
- 101000589305 Homo sapiens Natural cytotoxicity triggering receptor 2 Proteins 0.000 claims 2
- 101001124867 Homo sapiens Peroxiredoxin-1 Proteins 0.000 claims 2
- 101000692259 Homo sapiens Phosphoprotein associated with glycosphingolipid-enriched microdomains 1 Proteins 0.000 claims 2
- 101000702132 Homo sapiens Protein spinster homolog 1 Proteins 0.000 claims 2
- 101000633778 Homo sapiens SLAM family member 5 Proteins 0.000 claims 2
- 101000633784 Homo sapiens SLAM family member 7 Proteins 0.000 claims 2
- 101000914496 Homo sapiens T-cell antigen CD7 Proteins 0.000 claims 2
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 claims 2
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 claims 2
- 101000795169 Homo sapiens Tumor necrosis factor receptor superfamily member 13C Proteins 0.000 claims 2
- 101000648507 Homo sapiens Tumor necrosis factor receptor superfamily member 14 Proteins 0.000 claims 2
- 101000679857 Homo sapiens Tumor necrosis factor receptor superfamily member 3 Proteins 0.000 claims 2
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims 2
- 102000009490 IgG Receptors Human genes 0.000 claims 2
- 108010073807 IgG Receptors Proteins 0.000 claims 2
- 108060003951 Immunoglobulin Proteins 0.000 claims 2
- 102100039904 Integrin alpha-D Human genes 0.000 claims 2
- 102100022338 Integrin alpha-M Human genes 0.000 claims 2
- 102100022297 Integrin alpha-X Human genes 0.000 claims 2
- 108010041100 Integrin alpha6 Proteins 0.000 claims 2
- 108010030465 Integrin alpha6beta1 Proteins 0.000 claims 2
- 102100025304 Integrin beta-1 Human genes 0.000 claims 2
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims 2
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 claims 2
- 241000713666 Lentivirus Species 0.000 claims 2
- 102100024032 Linker for activation of T-cells family member 1 Human genes 0.000 claims 2
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 claims 2
- 102100034709 Lymphocyte cytosolic protein 2 Human genes 0.000 claims 2
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 2
- 102000027581 NK cell receptors Human genes 0.000 claims 2
- 108091008877 NK cell receptors Proteins 0.000 claims 2
- 102100022683 NKG2-C type II integral membrane protein Human genes 0.000 claims 2
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims 2
- 108010004217 Natural Cytotoxicity Triggering Receptor 1 Proteins 0.000 claims 2
- 108010004222 Natural Cytotoxicity Triggering Receptor 3 Proteins 0.000 claims 2
- 102100032870 Natural cytotoxicity triggering receptor 1 Human genes 0.000 claims 2
- 102100032851 Natural cytotoxicity triggering receptor 2 Human genes 0.000 claims 2
- 102100032852 Natural cytotoxicity triggering receptor 3 Human genes 0.000 claims 2
- 102100038082 Natural killer cell receptor 2B4 Human genes 0.000 claims 2
- 101710141230 Natural killer cell receptor 2B4 Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 102100026066 Phosphoprotein associated with glycosphingolipid-enriched microdomains 1 Human genes 0.000 claims 2
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 claims 2
- 102100029216 SLAM family member 5 Human genes 0.000 claims 2
- 102100029198 SLAM family member 7 Human genes 0.000 claims 2
- 102000008115 Signaling Lymphocytic Activation Molecule Family Member 1 Human genes 0.000 claims 2
- 102100027208 T-cell antigen CD7 Human genes 0.000 claims 2
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 claims 2
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims 2
- 108010065158 Tumor Necrosis Factor Ligand Superfamily Member 14 Proteins 0.000 claims 2
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims 2
- 102100024586 Tumor necrosis factor ligand superfamily member 14 Human genes 0.000 claims 2
- 102100029690 Tumor necrosis factor receptor superfamily member 13C Human genes 0.000 claims 2
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 claims 2
- 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 claims 2
- 102100022156 Tumor necrosis factor receptor superfamily member 3 Human genes 0.000 claims 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 2
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims 2
- 101001038499 Yarrowia lipolytica (strain CLIB 122 / E 150) Lysine acetyltransferase Proteins 0.000 claims 2
- 108010082017 alpha chain interleukin-7 receptor Proteins 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 102000003675 cytokine receptors Human genes 0.000 claims 2
- 108010057085 cytokine receptors Proteins 0.000 claims 2
- 102000018358 immunoglobulin Human genes 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 102000006495 integrins Human genes 0.000 claims 2
- 108010044426 integrins Proteins 0.000 claims 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 2
- 210000002751 lymph Anatomy 0.000 claims 2
- 210000004698 lymphocyte Anatomy 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims 2
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 claims 2
- 241000701161 unidentified adenovirus Species 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000008720 Bone Marrow Neoplasms Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 208000015943 Coeliac disease Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 claims 1
- 208000036566 Erythroleukaemia Diseases 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000035490 Megakaryoblastic Acute Leukemia Diseases 0.000 claims 1
- 208000035489 Monocytic Acute Leukemia Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000037538 Myelomonocytic Juvenile Leukemia Diseases 0.000 claims 1
- 208000014767 Myeloproliferative disease Diseases 0.000 claims 1
- 206010034016 Paronychia Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 208000021841 acute erythroid leukemia Diseases 0.000 claims 1
- 208000013593 acute megakaryoblastic leukemia Diseases 0.000 claims 1
- 208000020700 acute megakaryocytic leukemia Diseases 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 230000000735 allogeneic effect Effects 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 201000006491 bone marrow cancer Diseases 0.000 claims 1
- 201000010902 chronic myelomonocytic leukemia Diseases 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 201000005992 juvenile myelomonocytic leukemia Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 208000008585 mastocytosis Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 239000013612 plasmid Substances 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022035975A JP7561155B2 (ja) | 2016-04-01 | 2022-03-09 | Ｆｌｔ３に対するキメラ受容体及びその使用方法 |
| JP2024070373A JP2024105337A (ja) | 2016-04-01 | 2024-04-24 | Ｆｌｔ３に対するキメラ受容体及びその使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662317219P | 2016-04-01 | 2016-04-01 | |
| US62/317,219 | 2016-04-01 | ||
| PCT/US2017/025613 WO2017173410A1 (en) | 2016-04-01 | 2017-03-31 | Chimeric receptors to flt3 and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022035975A Division JP7561155B2 (ja) | 2016-04-01 | 2022-03-09 | Ｆｌｔ３に対するキメラ受容体及びその使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019516352A JP2019516352A (ja) | 2019-06-20 |
| JP2019516352A5 true JP2019516352A5 (enExample) | 2020-05-07 |
Family
ID=58530714
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018551409A Pending JP2019516352A (ja) | 2016-04-01 | 2017-03-31 | Ｆｌｔ３に対するキメラ受容体及びその使用方法 |
| JP2022035975A Active JP7561155B2 (ja) | 2016-04-01 | 2022-03-09 | Ｆｌｔ３に対するキメラ受容体及びその使用方法 |
| JP2024070373A Pending JP2024105337A (ja) | 2016-04-01 | 2024-04-24 | Ｆｌｔ３に対するキメラ受容体及びその使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022035975A Active JP7561155B2 (ja) | 2016-04-01 | 2022-03-09 | Ｆｌｔ３に対するキメラ受容体及びその使用方法 |
| JP2024070373A Pending JP2024105337A (ja) | 2016-04-01 | 2024-04-24 | Ｆｌｔ３に対するキメラ受容体及びその使用方法 |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US20190183931A1 (enExample) |
| EP (1) | EP3436479A1 (enExample) |
| JP (3) | JP2019516352A (enExample) |
| KR (2) | KR102694879B1 (enExample) |
| CN (1) | CN109641956A (enExample) |
| AR (2) | AR109626A1 (enExample) |
| AU (3) | AU2017240801A1 (enExample) |
| BR (1) | BR112018070187A8 (enExample) |
| CA (1) | CA3019655A1 (enExample) |
| CL (1) | CL2018002792A1 (enExample) |
| CO (1) | CO2018011804A2 (enExample) |
| CR (2) | CR20240116A (enExample) |
| EA (1) | EA201892193A1 (enExample) |
| IL (2) | IL296966A (enExample) |
| MA (1) | MA44507A (enExample) |
| MX (1) | MX2023013729A (enExample) |
| MY (2) | MY210545A (enExample) |
| NZ (1) | NZ746925A (enExample) |
| PE (2) | PE20241061A1 (enExample) |
| PH (1) | PH12018502118B1 (enExample) |
| SA (1) | SA518400154B1 (enExample) |
| SG (2) | SG11201808622SA (enExample) |
| TN (1) | TN2018000337A1 (enExample) |
| TW (2) | TWI776807B (enExample) |
| UA (1) | UA128326C2 (enExample) |
| WO (1) | WO2017173410A1 (enExample) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201116559D0 (en) | 2011-09-26 | 2011-11-09 | Univ Leuven Kath | Novel viral replication inhibitors |
| US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| US9725710B2 (en) | 2014-01-08 | 2017-08-08 | Flodesign Sonics, Inc. | Acoustophoresis device with dual acoustophoretic chamber |
| US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
| US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
| JOP20160086B1 (ar) | 2015-05-08 | 2021-08-17 | 2 Katholieke Univ Leuven Ku Leuven Research And Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JO3633B1 (ar) | 2015-09-16 | 2020-08-27 | Katholieke Univ Leuven Ku Leuven Research & Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JOP20160198B1 (ar) | 2015-09-16 | 2022-03-14 | Janssen Pharmaceuticals Inc | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| WO2017167950A1 (en) | 2016-03-31 | 2017-10-05 | Janssen Pharmaceuticals, Inc. | Substituted indole derivatives as dengue viral replication inhibitors |
| CR20180496A (es) | 2016-03-31 | 2018-12-06 | Univ Leuven Kath | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue |
| UA123276C2 (uk) | 2016-04-01 | 2021-03-10 | Кайт Фарма, Інк. | Химерний рецептор та спосіб лікування пухлини або злоякісного новоутворення |
| PT3436079T (pt) * | 2016-04-01 | 2021-10-06 | Kite Pharma Inc | Recetores de antigénios quiméricos e de células t e métodos de uso |
| WO2017173349A1 (en) | 2016-04-01 | 2017-10-05 | Kite Pharma, Inc. | Bcma binding molecules and methods of use thereof |
| CN109069482B (zh) | 2016-04-01 | 2022-04-05 | 杨森制药公司 | 作为登革热病毒复制抑制剂的经取代的吲哚化合物衍生物 |
| JOP20170069B1 (ar) | 2016-04-01 | 2021-08-17 | 1 Janssen Pharmaceuticals Inc | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
| AU2017382883B2 (en) | 2016-12-21 | 2024-07-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies specific for FLT3 and uses thereof |
| JOP20180026A1 (ar) | 2017-03-31 | 2019-01-30 | Univ Leuven Kath | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JOP20180025B1 (ar) | 2017-03-31 | 2021-08-17 | Janssen Pharmaceuticals Inc | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| PE20200342A1 (es) | 2017-05-22 | 2020-02-14 | Janssen Pharmaceuticals Inc | Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue |
| MX393586B (es) | 2017-05-22 | 2025-03-24 | Janssen Pharmaceuticals Inc | Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue |
| US12296012B2 (en) | 2017-06-02 | 2025-05-13 | Pfizer Inc. | Chimeric antigen receptors targeting FLT3 |
| ES2910969T3 (es) | 2017-08-03 | 2022-05-17 | Amgen Inc | Muteínas de interleucina-21 y métodos de tratamiento |
| ES2928576T3 (es) | 2017-09-08 | 2022-11-21 | Amgen Inc | Inhibidores de KRAS G12C y métodos de uso de los mismos |
| TW201930344A (zh) | 2018-01-12 | 2019-08-01 | 美商安進公司 | 抗ｐｄ-１抗體及治療方法 |
| JP7404331B2 (ja) * | 2018-03-23 | 2023-12-25 | ガビッシュ－ガリラヤ バイオ アプリケーションズ リミテッド | 膜結合型ＩＬ－１０をコードする核酸分子及びそれを発現する遺伝子的にリプログラミングされたＴｒｅｇ |
| UA129466C2 (uk) * | 2018-04-10 | 2025-05-07 | Емджен Інк. | Химерні рецептори до dll3 та способи їх застосування |
| JP7447014B2 (ja) | 2018-04-13 | 2024-03-11 | サンガモ セラピューティクス フランス | インターロイキン２３受容体に特異的なキメラ抗原受容体 |
| AU2019404098A1 (en) | 2018-12-18 | 2021-05-27 | Boehringer Ingelheim Io Canada Inc. | FLT3 agonist antibodies and uses thereof |
| JP2022526194A (ja) * | 2019-04-10 | 2022-05-23 | エレベートバイオ テクノロジーズ，インコーポレイテッド | Ｆｌｔ３特異的キメラ抗原受容体およびその使用方法 |
| CA3133333A1 (en) | 2019-04-30 | 2020-04-30 | Brian Scott GARRISON | Chimeric receptors and methods of use thereof |
| EP4076480A4 (en) * | 2019-12-16 | 2024-04-17 | Washington University | Chimeric antigen receptor dendritic cells (car-dcs) and methods of making and using same |
| WO2021212069A1 (en) * | 2020-04-17 | 2021-10-21 | City Of Hope | Flt3-targeted chimeric antigen receptor modified cells for treatment of flt3-positive malignancies |
| CN111808821B (zh) * | 2020-06-24 | 2022-06-14 | 南方医科大学珠江医院 | Flt3-nkg2d双靶点car-t的构建与制备 |
| WO2022140388A1 (en) | 2020-12-21 | 2022-06-30 | Allogene Therapeutics, Inc. | Protease-activating cd45-gate car |
| AU2022212090A1 (en) * | 2021-01-28 | 2023-07-06 | Allogene Therapeutics, Inc. | Methods for transducing immune cells |
| EP4284918A1 (en) | 2021-01-29 | 2023-12-06 | Allogene Therapeutics, Inc. | Knockdown or knockout of one or more of tap2, nlrc5, beta2m, trac, rfx5, rfxap and rfxank to mitigate t cell recognition of allogeneic cell products |
| CN116410315A (zh) * | 2021-12-31 | 2023-07-11 | 博生吉医药科技(苏州)有限公司 | 一种新型靶向人flt3的嵌合抗原受体修饰的t细胞的构建及应用 |
| CN119654406A (zh) | 2022-07-29 | 2025-03-18 | 艾洛基治疗公司 | 具有降低的基因表达以减轻免疫细胞识别的经工程化的细胞 |
| WO2025096560A1 (en) | 2023-10-30 | 2025-05-08 | Allogene Therapeutics, Inc. | Engineered cells |
| CN120157768A (zh) * | 2023-12-15 | 2025-06-17 | 博生吉安科细胞技术有限公司 | 一种识别flt3-car分子的单克隆抗体及其应用 |
| WO2026052582A1 (en) | 2024-09-04 | 2026-03-12 | Red Ridge Bio Ag | Biparatopic antibodies that specifically bind fms related receptor tyrosine kinase 3 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| WO1988001649A1 (en) | 1986-09-02 | 1988-03-10 | Genex Corporation | Single polypeptide chain binding molecules |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US6319494B1 (en) | 1990-12-14 | 2001-11-20 | Cell Genesys, Inc. | Chimeric chains for receptor-associated signal transduction pathways |
| IL104570A0 (en) | 1992-03-18 | 1993-05-13 | Yeda Res & Dev | Chimeric genes and cells transformed therewith |
| US5834266A (en) | 1993-02-12 | 1998-11-10 | President & Fellows Of Harvard College | Regulated apoptosis |
| US5869337A (en) | 1993-02-12 | 1999-02-09 | President And Fellows Of Harvard College | Regulated transcription of targeted genes and other biological events |
| US5830462A (en) | 1993-02-12 | 1998-11-03 | President & Fellows Of Harvard College | Regulated transcription of targeted genes and other biological events |
| US20030036654A1 (en) | 1994-08-18 | 2003-02-20 | Holt Dennis A. | Synthetic multimerizing agents |
| US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| AU4328801A (en) | 2000-02-24 | 2001-09-03 | Xcyte Therapies Inc | Simultaneous stimulation and concentration of cells |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US7446190B2 (en) * | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| TWI478940B (zh) * | 2005-08-26 | 2015-04-01 | Roche Glycart Ag | 具有經改變細胞傳訊活性之改質抗原結合分子 |
| US20100196336A1 (en) | 2006-05-23 | 2010-08-05 | Dongsu Park | Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods |
| JP5944831B2 (ja) * | 2009-12-23 | 2016-07-05 | シュニムネ ゲーエムベーハーＳＹＮＩＭＭＵＮＥ ＧｍｂＨ | 抗ｆｌｔ３抗体及びその使用方法 |
| US9089520B2 (en) | 2010-05-21 | 2015-07-28 | Baylor College Of Medicine | Methods for inducing selective apoptosis |
| US9845362B2 (en) * | 2010-10-08 | 2017-12-19 | The University Of North Carolina At Charlotte | Compositions comprising chimeric antigen receptors, T cells comprising the same, and methods of using the same |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| US9024028B2 (en) | 2011-01-26 | 2015-05-05 | Ariad Pharmaceuticals, Inc. | Methods and compositions for the synthesis of multimerizing agents |
| RU2688185C2 (ru) | 2011-03-23 | 2019-05-21 | Фред Хатчинсон Кэнсер Рисерч Сентер | Способ и композиции для клеточной иммунотерапии |
| US9359447B2 (en) * | 2012-03-23 | 2016-06-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-mesothelin chimeric antigen receptors |
| PT3613439T (pt) | 2013-02-15 | 2021-05-12 | Univ California | Recetor de antigénio quimérico e métodos de utilização do mesmo |
| AU2014236726A1 (en) | 2013-03-14 | 2015-09-17 | Bellicum Pharmaceuticals, Inc. | Methods for controlling T cell proliferation |
| JP6543626B2 (ja) | 2013-07-29 | 2019-07-10 | ブルーバード バイオ， インコーポレイテッド | 多部分シグナル伝達タンパク質およびその使用 |
| EP4420663A3 (en) | 2013-12-20 | 2024-10-30 | Novartis AG | Regulatable chimeric antigen receptor |
| JP6772063B2 (ja) | 2014-02-14 | 2020-10-21 | ベリカム ファーマシューティカルズ， インコーポレイテッド | 誘導可能なキメラポリペプチドを使用して細胞を活性化するための方法 |
| JP2017513818A (ja) * | 2014-03-15 | 2017-06-01 | ノバルティス アーゲー | キメラ抗原受容体を使用する癌の処置 |
| ES2743809T3 (es) * | 2014-07-31 | 2020-02-20 | Amgen Res Munich Gmbh | Constructos de anticuerpo monocatenarios biespecificos específicos de especies cruzadas optimizados |
| JP6657195B2 (ja) * | 2014-09-19 | 2020-03-04 | シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ | Ｌ１３Ｒα２を標的とする共刺激性キメラ抗原レセプターＴ細胞 |
| TWI829617B (zh) * | 2015-07-31 | 2024-01-21 | 德商安美基研究（慕尼黑）公司 | Ｆｌｔ３及ｃｄ３抗體構築體 |
| PT3436079T (pt) * | 2016-04-01 | 2021-10-06 | Kite Pharma Inc | Recetores de antigénios quiméricos e de células t e métodos de uso |
-
2017
- 2017-03-31 KR KR1020227012842A patent/KR102694879B1/ko active Active
- 2017-03-31 NZ NZ746925A patent/NZ746925A/en unknown
- 2017-03-31 TN TNP/2018/000337A patent/TN2018000337A1/en unknown
- 2017-03-31 EP EP17716764.0A patent/EP3436479A1/en active Pending
- 2017-03-31 CN CN201780033054.XA patent/CN109641956A/zh active Pending
- 2017-03-31 KR KR1020187031715A patent/KR102389096B1/ko active Active
- 2017-03-31 JP JP2018551409A patent/JP2019516352A/ja active Pending
- 2017-03-31 MA MA044507A patent/MA44507A/fr unknown
- 2017-03-31 US US16/090,562 patent/US20190183931A1/en not_active Abandoned
- 2017-03-31 EA EA201892193A patent/EA201892193A1/ru unknown
- 2017-03-31 AU AU2017240801A patent/AU2017240801A1/en not_active Abandoned
- 2017-03-31 PH PH1/2018/502118A patent/PH12018502118B1/en unknown
- 2017-03-31 CA CA3019655A patent/CA3019655A1/en active Pending
- 2017-03-31 PE PE2023001958A patent/PE20241061A1/es unknown
- 2017-03-31 UA UAA201810056A patent/UA128326C2/uk unknown
- 2017-03-31 PE PE2018001940A patent/PE20190201A1/es unknown
- 2017-03-31 WO PCT/US2017/025613 patent/WO2017173410A1/en not_active Ceased
- 2017-03-31 IL IL296966A patent/IL296966A/en unknown
- 2017-03-31 CR CR20240116A patent/CR20240116A/es unknown
- 2017-03-31 SG SG11201808622SA patent/SG11201808622SA/en unknown
- 2017-03-31 SG SG10201911963VA patent/SG10201911963VA/en unknown
- 2017-03-31 BR BR112018070187A patent/BR112018070187A8/pt active IP Right Grant
- 2017-03-31 MY MYPI2021006634A patent/MY210545A/en unknown
- 2017-03-31 CR CR20180518A patent/CR20180518A/es unknown
- 2017-03-31 MY MYPI2018001669A patent/MY201207A/en unknown
- 2017-03-31 IL IL262061A patent/IL262061B2/en unknown
- 2017-04-03 AR ARP170100839A patent/AR109626A1/es unknown
- 2017-04-05 TW TW106111460A patent/TWI776807B/zh active
- 2017-04-05 TW TW111130070A patent/TW202313669A/zh unknown
-
2018
- 2018-10-01 CL CL2018002792A patent/CL2018002792A1/es unknown
- 2018-10-01 MX MX2023013729A patent/MX2023013729A/es unknown
- 2018-10-01 SA SA518400154A patent/SA518400154B1/ar unknown
- 2018-10-31 CO CONC2018/0011804A patent/CO2018011804A2/es unknown
-
2022
- 2022-01-10 AU AU2022200108A patent/AU2022200108C1/en active Active
- 2022-03-09 JP JP2022035975A patent/JP7561155B2/ja active Active
- 2022-05-23 US US17/751,586 patent/US20230124464A1/en active Pending
- 2022-10-14 AR ARP220102800A patent/AR127371A2/es unknown
-
2024
- 2024-04-24 JP JP2024070373A patent/JP2024105337A/ja active Pending
- 2024-12-18 AU AU2024278538A patent/AU2024278538A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019516352A5 (enExample) | ||
| HRP20221348T1 (hr) | Kimerni receptori i postupci njihove uporabe | |
| JP2019515661A5 (enExample) | ||
| KR102879284B1 (ko) | 항-메소텔린 키메라 항원 수용체(car) 작제물 및 이의 용도 | |
| JP2017524367A5 (enExample) | ||
| JPWO2019200007A5 (enExample) | ||
| JP2017522879A5 (enExample) | ||
| JP2021000103A5 (enExample) | ||
| RU2017105160A (ru) | Лечение рака с помощью химерного антигенного рецептора к cd33 | |
| RU2017105065A (ru) | Лечение злокачественного новообразования с использованием гуманизированного химерного антигенного рецептора против всма | |
| RU2017105161A (ru) | Лечение рака с использованием химерного антигенного рецептора cll-1 | |
| IL277398B2 (en) | Pd-l1 binding affimers, and uses related thereto | |
| JPWO2020180591A5 (enExample) | ||
| JP2019523301A5 (enExample) | ||
| JP2020513839A5 (enExample) | ||
| JP2019525771A5 (enExample) | ||
| JP2019516350A5 (enExample) | ||
| JP2018538339A5 (enExample) | ||
| CA3032054A1 (en) | Combination therapies of chimeric antigen receptors and pd-1 inhibitors | |
| JP2019513370A5 (enExample) | ||
| RU2017108903A (ru) | Химерный антигенный рецептор (car) против cd123 для использования в лечении злокачественных опухолей | |
| RU2019128921A (ru) | Антитело к il-13ra2 и его применение | |
| EP4281566A1 (en) | Methods for high throughput screening of chimeric antigen receptors | |
| JP2020500903A5 (enExample) | ||
| US20250000976A1 (en) | Anti-bcma single domain antibodies and therapeutic constructs |